12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Company News  |  Deals

Alexion, Taligen Therapeutics deal

Alexion acquired Taligen for $111 million in cash, plus milestone payments for up to six products. Alexion gains Taligen's preclinical candidates...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >